Intraventricular treatment of relapsed and refractory central nervous system (CNS) lymphoma with rituximab.

被引：0
|
作者：
Schulz, H
Pels, H
Hom, E
Thall, A
Engert, A
机构：
[1] Univ Cologne, Clin Internal Med 1, Cologne, Germany
[2] Univ Bonn, Dept Neurol, D-5300 Bonn, Germany
[3] Idec Pharmaceut Corp, Clin Immunol, San Diego, CA USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4725
引用
收藏
页码：249B / 249B
页数：1
相关论文
共 50 条
  • [11] Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma
    Westin, Jason
    Nair, Ranjit
    Fayad, Luis
    Iyer, Swami P.
    Malpica, Luis
    Neelapu, Sattva S.
    Samaniego, Felipe
    Steiner, Raphael Eric
    Strati, Paolo
    Mathew, Shivon
    Griffith, Donna
    Nastoupil, Loretta J.
    Montinez, Wirt
    Rodriguez, Maria Alma
    Hagemeister, Frederick
    Feng, Lei
    Vega, Francisco
    Flowers, Christopher R.
    Ahmed, Sairah
    [J]. BLOOD, 2023, 142
  • [12] Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma
    Kadoch, Cigall
    Li, Jing
    Wong, Valerie S.
    Chen, Lingjing
    Cha, Soonmee
    Munster, Pamela
    Lowell, Clifford A.
    Shuman, Marc A.
    Rubenstein, James L.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (04) : 1029 - 1041
  • [13] Liposomal cytarabine in the treatment of primary or relapsed malignant lymphoma with central nervous system (CNS) involvement
    Thorsgaard, M.
    D'Amore, F.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 225 - 225
  • [14] Treatment of primary central nervous system lymphoma with a combination of intraventricular administration of rituximab and systemic chemotherapy.
    Wang, Shujie
    Zhang, Wei
    Lian, Wei
    Wu, Yongji
    Zou, Nong
    Zhu, Tienan
    Zhou, Daobin
    Xu, Ying
    Shen, Ti
    Zhao, Yongqiang
    [J]. BLOOD, 2006, 108 (11) : 256B - 256B
  • [15] New hopes in relapsed refractory primary central nervous system lymphoma
    Calimeri, Teresa
    Steidl, Carolina
    Fiore, Paolo
    Ferreri, Andres J. M.
    [J]. CURRENT OPINION IN ONCOLOGY, 2023, 35 (05) : 364 - 372
  • [16] Management of refractory or relapsed primary central nervous system lymphoma (Review)
    Yamanaka, Ryuya
    [J]. MOLECULAR MEDICINE REPORTS, 2009, 2 (06) : 879 - 885
  • [17] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Okita, Yoshiko
    Kano-Fujiwara, Rieko
    Nakatsuka, Shin-Ichi
    Honma, Keiichiro
    Kinoshita, Manabu
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [18] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Yoshiko Okita
    Rieko Kano-Fujiwara
    Shin-Ichi Nakatsuka
    Keiichiro Honma
    Manabu Kinoshita
    [J]. Experimental Hematology & Oncology, 10
  • [19] Treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma with a combination of a taxane, cyclophosphamide and rituximab.
    Krämer, A
    Zoz, M
    Krasniqi, F
    Görner, M
    Leo, E
    Ho, AD
    [J]. BLOOD, 2001, 98 (11) : 135A - 135A
  • [20] Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma
    Kaulen, Leon D.
    Gumbinger, Christoph
    Hinz, Felix
    Kessler, Tobias
    Winkler, Frank
    Bendszus, Martin
    Sahm, Felix
    Wick, Wolfgang
    [J]. NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
12345